不同剂量叶酸对不同MTHFR基因型缺血性脑卒中伴高同型半胱氨酸血症患者同型半胱氨酸水平的影响

摘要
图/表
参考文献(27)
相关文章 (15)

全文: PDF (555 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨不同剂量的叶酸对不同亚甲基四氢叶酸还原酶基因型缺血性脑卒中患者的高同型半胱氨酸血症的治疗效果，寻找合适的叶酸治疗方案。方法选取2017年1月—2019年12月新疆医科大学第一附属医院神经内科、康复医学科收治的伴有高同型半胱氨酸血症的缺血性脑卒中患者376例，将其进行亚甲基四氢叶酸还原酶C677T位点基因检测，分为TT型、CT型和CC型。根据随机数字表法分成高剂量叶酸组（188例，5.0 mg/d）与低剂量叶酸组（188例，0.8 mg/d），在治疗前、治疗4周后、治疗3个月后复测血清同型半胱氨酸水平。结果对CT及TT基因型，高剂量叶酸组在治疗4周后同型半胱氨酸水平低于低剂量叶酸组，差异有统计学意义（P ＜ 0.05）；治疗3个月后两组同型半胱氨酸水平比较，差异无统计学意义（P ＞ 0.05）；对CC基因型，在治疗前、治疗4周和3个月后，两组同型半胱氨酸水平比较，差异无统计学意义（P ＞ 0.05）。对于三种基因型，治疗4周、3个月后，两组同型半胱氨酸水平低于治疗前，治疗3个月后两组同型半胱氨酸水平低于治疗4周后，差异均有统计学意义（P ＜ 0.017）。结论对伴有高同型半胱氨酸血症缺血性脑卒中患者，应根据不同亚甲基四氢叶酸还原酶C677T基因型制订个性化叶酸治疗方案。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	卢晓燕任钰

关键词 ：亚甲基四氢叶酸还原酶基因C677T, 叶酸, 同型半胱氨酸, 缺血性脑卒中

Abstract：Objective To investigate the therapeutic effect of different doses of folic acid on the treatment of hyperhomocysteinemia in patients with different methylene tetrahydrofolate reductase genotypes of ischemic stroke, and to find an appropriate folic acid treatment scheme. Methods A total of 376 ischemic stroke patients with hyperhomocysteinemia who were admitted to the Department of Neurology and Rehabilitation Medicine of the First Affiliated Hospital of Xinjiang Medical University from January 2017 to December 2019 were selected. Methylene tetrahydrofolate reductase C677T site gene was detected, and they were divided into TT type, CT type and CC type. According to random number table, they were divided into high-dose folic acid group (188 cases, 5.0 mg/d) and low-dose folic acid group (188 cases, 0.8 mg/d). Blood homocysteine level was measured before treatment, four weeks after treatment, and three months after treatment. Results For CT and TT genotypes, the homocysteine level of the high-dose folic acid group was lower than that of the low-dose folic acid group after four weeks of treatment, the difference was statistically significant (P ＜ 0.05). After three months of treatment, there was no significant difference in homocysteine levels between the two groups (P ＞ 0.05). For CC genotype, there was no significant difference in homocysteine levels between the two groups before treatment, after four weeks and three months of treatment (P ＞ 0.05). For the three genotypes, after four weeks and three months of treatment, the homocysteine level in the two groups was lower than that before treatment, after three months of treatment, the homocysteine level in the two groups was lower than that after four weeks of treatment, the differences were statistically significant (P ＜ 0.017). Conclusion For patients with ischemic stroke with hyperhomocysteinemia, personalized folic acid therapy should be developed according to different methylene tetrahydrofolate reductase C677T genotypes.

Key words： methylene tetrahydrofolate reductase gene C677T Folic acid Homocysteine Ischemic stroke

基金资助:新疆维吾尔自治区自然科学基金联合基金项目（2016D01C327）。

通讯作者: 任钰（1983.3-），女，副主任医师，硕士；研究方向：神经系统疾病的康复。

作者简介: 卢晓燕（1994.5-），女，硕士；研究方向：神经系统疾病的康复。

引用本文:

卢晓燕任钰. 不同剂量叶酸对不同MTHFR基因型缺血性脑卒中伴高同型半胱氨酸血症患者同型半胱氨酸水平的影响[J]. 中国医药导报, 2021, 18(17): 90-93.
LU Xiaoyan REN Yu. Effects of different doses of folic acid on homocysteine levels in patients with different MTHFR genotypes of ischemic stroke with hyperhomocysteinemia. 中国医药导报, 2021, 18(17): 90-93.

链接本文:

https://www.yiyaodaobao.com.cn/CN/ 或 https://www.yiyaodaobao.com.cn/CN/Y2021/V18/I17/90

[1] Tan X，Zhang Y，Shao H. Healthy China 2030，a breakthrough for improving health [J]. Glob Health Promot，2019，26（4）：96-99.
[2] Zhou M，Wang H，Zeng X，et al. Mortality，morbidity，and risk factors in China and its provinces，1990-2017： a systematic analysis for the Global Burden of Disease Study 2017 [J]. Lancet，2019，394（10204）：1145-1158.
[3] GBD 2016 Stroke Collaborators. Global，regional，and national burden of stroke，1990-2016：a systematic analysis for the Global Burden of Disease Study 2016 [J]. Lancet Neurol，2019，18（5）：439-458.
[4] 中国心血管健康与疾病报告编写组.中国心血管健康与疾病报告2019概要[J].中国循环杂志，2020，35（9）：833-854.
[5] 庞利红.高同型半胱氨酸与脑梗死的相关性研究[J].中国实用神经疾病杂志，2017，20（6）：70-72.
[6] Mao X，Han L. The Relationship of Methylenetetrahydrofolate Reductase Gene C677T Polymorphism and Ischemic Stroke in Chinese Han Population [J]. Ann Clin Lab Sci，2018，48（2）：242-247.
[7] 中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2018[J].中华神经科杂志，2018，51（9）：666-682.
[8] McNulty H，Ward M，Hoey L，et al. Addressing optimal folate and related B-vitamin status through the lifecycle： health impacts and challenges [J]. Proc Nutr Soc，2019，78（3）：449-462.
[9] Hickey SE，Curry CJ，Toriello HV. ACMG Practice Guideline：lack of evidence for MTHFR polymorphism testing [J]. Genet Med，2013，15（2）：153-156.
[10] 王新德.各类脑血管疾病诊断要点[J].中华神经科杂志，1996，29（6）: 379-380.
[11] 陈孝平,汪建平.外科学.第8版[M].人民卫生出版社, 2013：196-197.
[12] Ward M，Hughes CF，Strain JJ，et al. Impact of the common MTHFR 677C→T polymorphism on blood pressure in adulthood and role of riboflavin in modifying the genetic risk of hypertension：evidence from the JINGO project [J]. BMC Med，2020，18（1）：318.
[13] Hsu CY，Chiu SW，Hong KS，et al. Folic Acid in Stroke Prevention in Countries without Mandatory Folic Acid Food Fortification：A Meta-Analysis of Randomized Controlled Trials [J]. J Stroke，2018，20（1）：99-109.
[14] Huo Y，Li J，Qin X，et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China：the CSPPT randomized clinical trial [J]. JAMA，2015，313（13）：1325-1335.
[15] Zhang T，Lin T，Wang Y，et al. Estimated Stroke-Free Survival of Folic Acid Therapy for Hypertensive Adults： Projection Based on the CSPPT [J]. Hypertension，2020， 75（2）：339-346.
[16] Huang X，Qin X，Yang W，et al. MTHFR Gene and Serum Folate Interaction on Serum Homocysteine Lowering： Prospect for Precision Folic Acid Treatment [J]. Arterioscler Thromb Vasc Biol，2018，38（3）：679-685.
[17] Yang X，Zhang M，Song R，et al. The modifying effect of the MTHFR genotype on the association between folic acid supplementation and pulse wave velocity：Findings from the CSPPT [J]. Cardiovasc Ther，2018，36（6）：e12473.
[18] Qin X，Spence JD，Li J，et al. Interaction of serum vitamin B12 and folate with MTHFR genotypes on risk of ischemic stroke [J]. Neurology，2020，94（11）：e1126-e1136.
[19] 围受孕期增补叶酸预防神经管缺陷指南工作组.围受孕期增补叶酸预防神经管缺陷指南（2017）[J].中国生育健康杂志，2017，28（5）：401-410.
[20] Bailey RL，Mills JL，Yetley EA，et al. Unmetabolized serum folic acid and its relation to folic acid intake from diet and supplements in a nationally representative sample of adults aged > or =60 y in the United States [J]. Am J Clin Nutr，2010，92（2）：383-389.
[21] Steluti J，Reginaldo C，Selhub J，et al. Presence of circulating folic acid in plasma and its relation with dietary intake，vitamin B complex concentrations and genetic variants [J]. Eur J Nutr，2019，58（8）：3069-3077.
[22] Cornet D，Clement A，Clement P，et al. High doses of folic acid induce a pseudo-methylenetetrahydrofolate syndrome [J]. SAGE Open Med Case Rep，2019，7：2050313X19850435.
[23] Reynolds EH. What is the safe upper intake level of folic acid for the nervous system? Implications for folic acid fortification policies [J]. Eur J Clin Nutr，2016，70（5）：537-540.
[24] 卢晓燕.叶酸治疗TT基因型和CC基因型缺血性脑卒中患者HHcy的对比研究[D].乌鲁木齐：新疆医科大学，2020.
[25] Du B，Tian H，Tian D，et al. Genetic polymorphisms of key enzymes in folate metabolism affect the efficacy of folate therapy in patients with hyperhomocysteinaemia [J]. Br J Nutr，2018，119（8）：887-895.
[26] Wang B，Wu H，Li Y，et al. Effect of long-term low-dose folic acid supplementation on degree of total homocysteine-lowering： major effect modifiers [J]. Br J Nutr，2018， 120（10）：1122-1130.
[27] Coppedè F，Stoccoro A，Tannorella P，et al. Plasma Homocysteine and Polymorphisms of Genes Involved in Folate Metabolism Correlate with DNMT1 Gene Methylation Levels [J]. Metabolites，2019，9（12）：298.